HEALTH SERVICES KENTUCKY CABINET FOR: $113M Department of Health and Human Services Grant
Summary
This $113M grant to the Kentucky Cabinet for Health and Family Services funds the state's opioid and stimulant overdose response effort. As the recipient is a state government entity, no publicly traded company is directly impacted, though the broader healthcare sector may see indirect benefits from sustained federal investment in substance abuse treatment infrastructure.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The $113M grant is a non-commercial award to a state government, not a public company.
- 2.Federal opioid response spending continues but with no direct public equity beneficiaries from this specific award.
- 3.Investors should monitor broader legislative trends (e.g., SAMHSA appropriations) rather than this single contract for sector signals.
Market Implications
This contract has negligible direct market implications. The $113M award flows to state government operations and subcontractors that are not publicly listed. The healthcare sector may see a mild, diffuse tailwind from sustained federal spending on addiction treatment, but no specific ticker moves are attributable. Investors should look for contracts where public companies are named recipients or prime contractors to capture revenue impact.
Full Analysis
The contract is a project grant awarded by the Substance Abuse and Mental Health Services Administration (SAMHSA) to the Kentucky Cabinet for Health and Family Services. The $113M award supports the Kentucky Overdose Response Effort (KORE) over three years, focusing on evidence-based prevention, treatment, and recovery services for opioid and stimulant use disorders. The state agency is not a publicly traded entity, so no direct stock market impact exists from this award. However, the contract reflects ongoing federal prioritization of the opioid crisis, which sustains demand for related healthcare services and pharmaceuticals, such as medications for opioid use disorder (MOUD). Companies like Indivior ($INDV) or Alkermes ($ALKS) that manufacture addiction treatments could see downstream benefits, but the contract does not name them as subcontractors. No related bills in the provided list directly connect to this opioid response funding, so legislative tailwinds are absent. The grant is purely a state-level operational funding stream, not a procurement contract, meaning it does not generate direct revenue for public companies. The impact on financial markets is minimal and indirect.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DEPARTMENT OF HUMAN SERVICES HAWAII: $2.2B Department of Health and Human Services Grant
KANSAS DEPARTMENT OF HEALTH & ENVIRONMENT: $4.6B Department of Health and Human Services Grant
NEW MEXICO HEALTH CARE AUTHORITY: $9.4B Department of Health and Human Services Grant
HEALTH SERVICES KENTUCKY CABINET FOR: $18.2B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.1B Department of Health and Human Services Federal Award
ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM: $19.6B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
HEALTH CARE SERVICES, CALIFORNIA DEPARTMENT OF: $6.2B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Contract Details
Recipient
HEALTH SERVICES KENTUCKY CABINET FOR
Award Amount
$112,972,692
Awarding Agency
Department of Health and Human Services
Sub-Agency
Substance Abuse and Mental Health Services Administration
Contract Type
PROJECT GRANT (B)
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →